View abstract

This abstract is assigned to session Poster session in O'Bistro

Title

Intravitreal bevacizumab induced uveitis: report of 2 cases

Purpose	To report 2 cases of intravitreal bevacizumab induced uveitis and review of the literature.
Methods	Study of medical records and literature.
Results	The first patient treated for neovascular age-related macular degeneration (nAMD), developed anterior uveitis within 12 hours following the 5th intravitreal injection of bevacizumab (IVB). The second patient treated for nAMD developed a hypertensive anterior uveitis within 2 hours after the 9th IVB administration. In both cases the uveitis resolved within a week under topical prednisolone treatment. No recurrences were noticed after repeated intravitreal ranibizumab injections (case 2). The risk of developing uveitis after IVB is approximately 0,1%. An immunological response to the drug or a contaminant is generally believed to be its cause. Bevacizumab and ranibizumab are molecules with different chemical and biological properties, between which no immunological cross reactions have been reported yet. Uveitis after IVB occurs within 1 day, presenting with ocular pain, conjunctival injection, corneal edema, anterior chamber and vitreous cells. Topical prednisolone therapy leads to complete resolution of the inflammation within 1-2 weeks. In contrast, infectious endophthalmitis presents 1 to 6 days after intravitreal injection and has a worse prognosis even after adequate treatment.
Conclusion	Uveitis after IVB is rare, occuring within 24 hours and responding to topical prednisolone. Relapses have not been reported after subsequent intravitreal ranibizumab administration.

Authors 1

Last name	VANDEWEYER
Initials	E
Department	Universitair Ziekenhuis Antwerpen
City	Edegem

Authors 2

Last name	SMETS
Initials	RME
Department	Universitair Ziekenhuis Antwerpen
City	Edegem